GlassScriptPhysician profile
Tenzin Youlo
NPI 1356054761
$1,251.92
in general payments reported to CMS, 2019-2025
14 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $226 · 2024: $494 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $395.08 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Evoque |
| Abiomed | $251.88 | 2025 | |
| Impulse Dynamics (USA) INC. | $168.61 | 2024 | Optimizer |
| Abbott Laboratories | $111.45 | 2023-2024 | Cardiomems, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $67.47 | 2023 | Spravato |
| Boston Scientific Corporation | $40.67 | 2024 | Watchman Flx |
| Novo Nordisk INC | $39.58 | 2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $32.53 | 2023 | Breztri, Farxiga |
| Philips North America LLC | $31.85 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Ibsa Pharma INC. | $31.58 | 2023 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.86 | 2023 | Jardiance |
| Abbvie INC. | $23.65 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.28 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $15.43 | 2023 | Shingrix, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tenzin Youlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.